Capital Group Private Client Services Inc. Takes $2.94 Million Position in DexCom, Inc. (NASDAQ:DXCM)

Capital Group Private Client Services Inc. acquired a new stake in DexCom, Inc. (NASDAQ:DXCMGet Rating) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 5,736 shares of the medical device company’s stock, valued at approximately $2,935,000.

A number of other hedge funds have also recently added to or reduced their stakes in the company. PFS Investments Inc. boosted its holdings in DexCom by 54.0% during the first quarter. PFS Investments Inc. now owns 796 shares of the medical device company’s stock worth $407,000 after buying an additional 279 shares in the last quarter. Centaurus Financial Inc. boosted its holdings in DexCom by 5.5% during the first quarter. Centaurus Financial Inc. now owns 1,236 shares of the medical device company’s stock worth $632,000 after buying an additional 64 shares in the last quarter. Industrial Alliance Investment Management Inc. boosted its holdings in DexCom by 11.1% during the first quarter. Industrial Alliance Investment Management Inc. now owns 5,590 shares of the medical device company’s stock worth $2,860,000 after buying an additional 557 shares in the last quarter. Jaffetilchin Investment Partners LLC boosted its holdings in DexCom by 7.7% during the first quarter. Jaffetilchin Investment Partners LLC now owns 1,412 shares of the medical device company’s stock worth $440,000 after buying an additional 101 shares in the last quarter. Finally, GM Advisory Group Inc. purchased a new stake in DexCom during the first quarter worth $2,737,000. 92.34% of the stock is owned by hedge funds and other institutional investors.

DexCom Trading Up 1.4 %

Shares of DXCM opened at $92.89 on Monday. The company has a current ratio of 4.72, a quick ratio of 4.30 and a debt-to-equity ratio of 0.87. DexCom, Inc. has a 12-month low of $66.89 and a 12-month high of $164.86. The firm has a 50-day moving average price of $84.40 and a 200 day moving average price of $92.32. The firm has a market capitalization of $36.47 billion, a P/E ratio of 193.52, a P/E/G ratio of 3.75 and a beta of 1.03.

DexCom (NASDAQ:DXCMGet Rating) last announced its quarterly earnings data on Thursday, July 28th. The medical device company reported $0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.02). DexCom had a net margin of 7.47% and a return on equity of 11.79%. The firm had revenue of $696.20 million during the quarter, compared to analysts’ expectations of $709.33 million. During the same period in the prior year, the company posted $0.19 EPS. The company’s revenue for the quarter was up 17.0% compared to the same quarter last year. Sell-side analysts forecast that DexCom, Inc. will post 0.79 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have weighed in on DXCM. Citigroup reduced their price objective on shares of DexCom from $105.00 to $100.00 in a research report on Friday, July 29th. Wells Fargo & Company reduced their price objective on shares of DexCom from $144.00 to $102.00 in a research report on Friday, July 29th. Cowen restated a “buy” rating and set a $85.00 price objective on shares of DexCom in a research report on Friday, July 29th. Morgan Stanley reduced their price objective on shares of DexCom from $91.00 to $83.00 and set an “equal weight” rating for the company in a research report on Friday, July 29th. Finally, Robert W. Baird reduced their price objective on shares of DexCom from $115.00 to $97.00 in a research report on Friday, July 29th. Two equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to data from MarketBeat, DexCom has an average rating of “Moderate Buy” and a consensus target price of $115.23.

Insider Activity at DexCom

In related news, Director Steven Robert Pacelli sold 1,000 shares of the company’s stock in a transaction dated Monday, July 25th. The shares were sold at an average price of $83.07, for a total value of $83,070.00. Following the completion of the sale, the director now owns 138,700 shares of the company’s stock, valued at $11,521,809. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last quarter, insiders sold 3,000 shares of company stock valued at $239,830. 0.41% of the stock is owned by company insiders.

DexCom Profile

(Get Rating)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system.

Recommended Stories

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.